Opinion on Therapy Area in North America

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

ZymoGenetics: rhThrombin has great potential

In line with the rapid historical uptake of other recombinant protein products, following an anticipated approval in late 2007, ZymoGenetics' rhThrombin is expected to quickly take market share from King Pharmaceutical's Thrombin-JMI. Upon doing so, rhThrombin's revenues are forecast to grow from $165 million in 2008 to an impressive $459 million in 2010, well ahead of Wall Street consensus.

Published By Datamonitor
13 Apr 2006
CommentWire
CommentWire

ZymoGenetics: early hope for late-stage disease

ZymoGenetics has reported positive results from its phase Ia study of IL-21 in patients with metastatic melanoma and metastatic renal cell carcinoma. This announcement warrants further studies of IL-21 in these indications, which is welcome news for ZymoGenetics and development partner Novo Nordisk. However, competition is already on the horizon, in the form of Bayer/Onyx' Nexavar.

Published By Datamonitor
15 Nov 2005
CommentWire
CommentWire

ZymeTx: flu management program could be catching

Published By Datamonitor
17 Apr 2001
Expert View
Expert View

Zelboraf's approval demonstrates a significant shift toward personalized cancer therapy

The FDA has approved Zelboraf and Roche's companion diagnostic test for BRAF V600E mutation-positive metastatic melanoma. The joint approval is the first example of co-development and demonstrates the movement toward personalized cancer therapy, and Zelboraf's impressive efficacy data and the availability of a test will ensure rapid uptake.

Published By Datamonitor
18 Aug 2011
CommentWire
CommentWire

Xolair: breathing easy over FDA approval

Xolair, developed by Genentech, Novartis and Tanox, reduces the number of attacks in severe allergic asthmatics. However prescribing restrictions, safety concerns and high cost are expected to limit sales to $593 million by 2010. The drug's best chance of success is through label extensions for pediatric use and for allergic rhinitis.<BR />

Published By Datamonitor
19 May 2003
Expert View
Expert View

Xigris: struggling to overcome its problems

The once lauded drug Xigris is struggling to recover from a series of setbacks, despite existing in a potentially lucrative market with little competition. After disappointing US sales, Xigris has now been launched in Europe. Datamonitor's Michael Randle asks if Eli Lilly can take advantage of its status as the only approved severe sepsis treatment and breathe new life into its sleeping giant.

Published By Datamonitor
15 Nov 2002
Expert View
Expert View

Xigris: Lilly's sepsis flop misses out

Eli Lilly's Xigris sales have proved disappointing, for the year-to-date period ending February 28 2002 sales reached just $14 million, bringing total sales to $35 million since the drug's launch in late November 2001. Industry analysts had predicted sales of between $300 and $500 million in 2002, but this now seems unrealistic, so where did it all go wrong?

Published By Datamonitor
22 Mar 2002
CommentWire
CommentWire

Xenova/QLT: tackling multidrug resistance

UK biotech Xenova and its North American ally QLT will trial tariquidar for multidrug resistance in non-small cell lung cancer. As long as the results are positive, tariquidar should have a bright future: multidrug resistance is an increasingly serious problem in cancer treatment, and the developers look set to provide strong marketing support.

Published By Datamonitor
11 Jul 2002
Expert View
Expert View

Xarelto data raise questions at the 2010 American Heart Association Scientific Sessions

Results from the ROCKET-AF trial of Xarelto in stroke prevention in atrial fibrillation have been presented at this year's Scientific Sessions of the American Heart Association. While positive, the data show that Xarelto has by no means outperformed Pradaxa. Clinicians may start to see the two drugs as complementary alternatives, based on their respective performance in various subgroups.

Published By Datamonitor
16 Nov 2010
CommentWire
CommentWire

Xanthus: more hurdles to clear for Symadex

Xanthus Life Sciences has begun dosing patients in a phase II trial of Symadex in recurrent colorectal cancer. While this is clearly a positive step in Symandex' development, the drug candidate still has phase III trials to contend with and, even if Symandex proves fit for launch here, Xanthus will need to find a marketing partner to help it achieve commercial success in the tough cancer market.

Published By Datamonitor
17 Jan 2006

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.